Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Warner Chilcott, Actavis Inc. deal

    Warner Chilcott plc, Dublin, Ireland Actavis Inc., Parsippany, N.J. Business: Generics, Pharmaceuticals Generics company Actavis completed its acquisition of specialty pharma Warner Chilcott in a stock deal that values …

    Published on 10/7/2013
  • X-Chem, AstraZeneca deal

    X-Chem Inc., Waltham, Mass. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Business: Pharmaceuticals AstraZeneca elected to extend a May 2012 research deal to five years from two years. X-Chem will conduct drug …

    Published on 10/7/2013
  • Xention, Servier deal

    Xention Ltd., Cambridge, U.K. Servier, Neuilly-sur-Seine, France Business: Cardiovascular Xention granted Servier an option to acquire rights to develop and commercialize XEN-D0103 for atrial fibrillation (AF), …

    Published on 10/7/2013
  • Acton Pharmaceuticals, Meda deal

    Acton Pharmaceuticals Inc., Marlborough, Mass. Meda AB (SSE:MEDAA), Solna, Sweden Business: Inflammation Meda will acquire Acton for $135 million in cash plus a $10 million near-term undisclosed development milestone. …

    Published on 9/2/2013
  • Adimab, Celgene, Innovent Biologics deal

    Adimab LLC, Lebanon, N.H. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Innovent Biologics Inc., Suzhou, China Business: Antibodies Adimab announced two separate discovery deals for its yeast-based antibody discovery …

    Published on 9/2/2013
  • Advanomics, Sunshine Biopharma, Laboratoires Garmen Inc. deal

    Advanomics Corp., Montreal, Quebec Sunshine Biopharma Inc. (OTCQB:SBFM), Montreal, Quebec Laboratoires Garmen Inc., Montreal, Quebec Business: Cancer Sunshine said its Advanomics parent company will acquire Garmen for …

    Published on 9/2/2013
  • Akorn, Hi-Tech Pharmacal deal

    Akorn Inc. (NASDAQ:AKRX), Lake Forest, Ill. Hi-Tech Pharmacal Co. Inc. (NASDAQ:HITK), Amityville, N.Y. Business: Generics Akorn will acquire generics company Hi-Tech for $640 million in cash, or $43.50 per Hi-Tech share…

    Published on 9/2/2013
  • Altus Formulation Inc., Paladin deal

    Altus Formulation Inc., Montreal, Quebec Paladin Labs Inc. (TSX:PLB), Montreal, Quebec Business: Neurology, Supply/Service Paladin disclosed in its 2Q13 earnings that it holds a 35% equity stake in Altus and also has an…

    Published on 9/2/2013
  • Amgen, Onyx deal

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Onyx Pharmaceuticals Inc. (NASDAQ:ONXX), South San Francisco, Calif. Business: Cancer The companies said Amgen will acquire Onyx for $125 per share in cash, or about $10.4…

    Published on 9/2/2013
  • Amplimmune, AstraZeneca deal

    Amplimmune Inc., Gaithersburg, Md. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Business: Cancer AstraZeneca's MedImmune LLC biologics unit will acquire cancer immunotherapy company Amplimmune for $225 million up …

    Published on 9/2/2013
  • Aradigm, Grifols deal

    Aradigm Corp. (OTCBB:ARDM), Hayward, Calif. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS), Barcelona, Spain Business: Pulmonary The partners closed their May deal granting Grifols exclusive, worldwide rights to develop and …

    Published on 9/2/2013
  • Aragon Pharmaceuticals, Seragon, J&J deal

    Aragon Pharmaceuticals Inc., San Diego, Calif. Seragon Pharmaceuticals Inc., San Diego, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Cancer Johnson & Johnson completed its acquisition of cancer …

    Published on 9/2/2013
  • Arcturus Therapeutics, Marina Biotech deal

    Arcturus Therapeutics Inc., San Diego, Calif. Marina Biotech Inc. (OTCQX:MRNA), Bothell, Wash. Business: Chemistry Marina sold its Unlocked Nucleobase Analog (UNA) patents for the development of RNAi therapeutics to …

    Published on 9/2/2013
  • Argos, Green Cross, Pharmstandard deal

    Argos Therapeutics Inc., Durham, N.C. Green Cross Corp. (KSE:006280), Yongin-si, South Korea Pharmstandard OJSC (RTS:PHST; LSE:PHST), Dolgoprudny, Russia Business: Cancer Argos granted exclusive commercialization rights…

    Published on 9/2/2013
  • Bever Pharmaceutical Pte. Ltd., Pharmstandard deal

    Bever Pharmaceutical Pte. Ltd., Singapore Pharmstandard OJSC (RTS:PHST; LSE:PHST), Dolgoprudny, Russia Business: Pharmaceuticals Pharmstandard completed the acquisition of Bever for $590 million comprised of $542 …

    Published on 9/2/2013
  • Biobehavioral Diagnostics, Pearson plc deal

    BioBehavioral Diagnostics Co., Westford, Mass. Pearson plc (NYSE:PSO; LSE:PSON), London, U.K. Business: Diagnostic Educational material and services company Pearson acquired substantially all of the assets of …

    Published on 9/2/2013
  • Boca Pharmacal LLC, Endo deal

    Boca Pharmacal LLC, Coral Springs, Fla. Endo Health Solutions Inc. (NASDAQ:ENDP), Chadds Ford, Pa. Business: Generics Endo's Generics International Inc. subsidiary will acquire generics company Boca Pharmacal for $225 …

    Published on 9/2/2013
  • Carolus, The Alpha-1 Foundation deal

    Carolus Therapeutics Inc., San Diego, Calif. The Alpha-1 Foundation, Miami, Fla. Business: Inflammation, Pulmonary Carolus partnered with the not-for-profit's The Alpha-1 Project (TAP) Inc. subsidiary to characterize …

    Published on 9/2/2013
  • Ceregene, Sangamo deal

    Ceregene Inc., San Diego, Calif. Sangamo BioSciences Inc. (NASDAQ:SGMO), Richmond, Calif. Business: Neurology, Gene/Cell therapy Sangamo will acquire gene therapy company Ceregene for 100,000 shares of Sangamo stock, or…

    Published on 9/2/2013
  • Certara, The Hamner Institutes for Health Sciences deal

    Certara L.P., St. Louis, Mo. The Hamner Institutes for Health Sciences, Research Triangle Park, N.C. Business: Hepatic Certara and not-for-profit Hamner partnered to develop a model that will help researchers assess the…

    Published on 9/2/2013
  • Chiesi, Zymenex deal

    Chiesi Farmaceutici S.p.A., Parma, Italy Zymenex A/S, Hillerod, Denmark Business: Endocrine/Metabolic Chiesi will acquire Zymenex for an undisclosed amount. Chiesi will gain Zymenex's Lamazym (rhLaman), a recombinant …

    Published on 9/2/2013
  • CrystalGenomics, Hwail deal

    CrystalGenomics Inc. (KOSDAQ:083790), Seongnam, South Korea Hwail Pharmaceutical Co. Ltd. (KOSDAQ:061250), Hwaseong-Si, South Korea Business: Pharmaceuticals CrystalGenomics acquired a majority stake in API manufacturer…

    Published on 9/2/2013
  • Eli Lilly, Humana Inc. deal

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Humana Inc. (NYSE:HUM), Louisville, Ky. Business: Other Eli Lilly and insurer Humana partnered to conduct research using de-identified patient data to improve healthcare …

    Published on 9/2/2013
  • Endosense, St. Jude Medical deal

    Endosense S.A., Geneva, Switzerland St. Jude Medical Inc. (NYSE:STJ), St. Paul, Minn. Business: Cardiovascular Medical device company St. Jude acquired Endosense for CHF159 million ($171.8 million) up front, plus up to …

    Published on 9/2/2013
  • EpiCept, Immune Pharmaceuticals deal

    EpiCept Corp., Tarrytown, N.Y. Immune Pharmaceuticals Ltd., Herzliya-Pituach, Israel Business: Pharmaceuticals The companies completed their merger into combined company Immune Pharmaceuticals Inc. Immune …

    Published on 9/2/2013

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993